Skip to Main Content

Paper Details

Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling.
Cancer Discov
30
2021
Author NameAffiliation
Peter Man-Un UngDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai
Celina AngThe Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Brian D BrownPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai
Avner SchlessingerDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai
Avner SchlessingerDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai
Meenhard HerlynThe Wistar Institute
David E Shaw
David E ShawColumbia University
  • 1 - 8

Datasets